SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 2001; 1: 497510.
  • 2
    Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 8995.
  • 3
    Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 11758.
  • 4
    Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 313.
  • 5
    Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 45564.
  • 6
    Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61: 864750.
  • 7
    Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 2001; 94: 24351.
  • 8
    D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in β2m gene expression. J Clin Invest 1991; 87: 28492.
  • 9
    Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998; 52: 5209.
  • 10
    Perez B, Benitez R, Fernandez MA, Oliva MR, Soto JL, Serrano S, Lopez Nevot MA, Garrido F. A new beta2-microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999; 53: 56972.
  • 11
    Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998; 101: 27209.
  • 12
    Goodfellow PN, Jones EA, Van Heyningen V, Solomon E, Bobrow M, Miggiano V, Bodmer WF. The beta2-microglobulin gene is on chromosome 15 and not in the HLA region. Nature 1975; 254: 2679.
  • 13
    Mendez R, Serrano A, Jager E, Maleno I, Ruiz-Cabello F, Knuth A, Garrido F. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 2001; 57: 50819.
  • 14
    Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978; 14: 920.
  • 15
    Lopez-Nevot MA, Cabrera T, de la Higuera B, Ruiz-Cabello F, Garrido F. Production and characterization of monoclonal antibodies against leukemic cells. Immunologia 1986; 5: 519.
  • 16
    Spear BT, Kornbluth J, Strominger JL, Wilson DB. Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131. J Exp Med 1985; 162: 180210.
  • 17
    Burrone OR, Kefford RF, Gilmore D, Milstein. Stimulation of HLA-A, B, C by IFN-alpha. The derivation of Molt 4 variants and the differential expression of HLA-A, B, C subsets. EMBO J 1985; 4: 285560.
  • 18
    Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 2000; 61: 100112.
  • 19
    Torres LM, Cabrera T, Concha A, Oliva MR, Ruiz-Cabello F, Garrido F. HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens 1993; 41: 651.
  • 20
    Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998; 161: 698592.
  • 21
    Sun Y, Song M, Stevanovic S, Jankowiak C, Paschen A, Rammensee HG, Schadendorf D. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer 2000; 87: 399404.
  • 22
    Geertsen R, Boni R, Blasczyk R, Romero P, Betts D, Rimoldi D, Hong X, Laine E, Willers J, Dummer R. Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations. Int J Cancer 2002; 99: 827.
  • 23
    Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, Garcia A, Ruiz-Cabello F, Garrido F. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999; 83: 917.
  • 24
    Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 3407.
  • 25
    Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real FX, Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996; 47: 37281.
  • 26
    Blanchet O, Bourge JF, Zinszner H, Israel A, Kourilsky P, Dausset J, Degos L, Paul P. Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc Natl Acad Sci USA 1992; 89: 348892.
  • 27
    Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 2001; 91: 10919.
  • 28
    French LE, Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 2002; 12: 515.
  • 29
    Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001; 98: 1151520.
  • 30
    Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000; 164: 126976.
  • 31
    Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, Zeuthen J, Garrido F, Ruiz-Cabello F. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 2001; 49: 6218.
  • 32
    Willers J, Haffner A, Zepter K, Storz M, Urosevic M, Burg G, Dummer R. The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumor cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulation. J Invest Dermatol 2001; 116: 8749.
  • 33
    Kurnick JT, Ramirez-Montagut T, Boyle LA, Andrews DM, Pandolfi F, Durda PJ, Butera D, Dunn IS, Benson EM, Gobin SJ, van den Elsen PJ. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol 2001; 167: 120411.
  • 34
    Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000; 48: 66172.